Menopausal dyslipoproteinemia in breast carcinoma patients: a laboratory analysis
DOI:
https://doi.org/10.18203/2320-1770.ijrcog20174425Keywords:
Breast cancer, Cholesterol, HDL, Lipoproteins, LDL, MenopauseAbstract
Background: Seldom any precedent work has aimed to study the influence of age and menopausal status towards serum lipoproteins levels in breast cancer. Owing to influence of sex-steroids over lipid handling by oestrogen-dependent breast cells, their serum levels might reveal insinuating facts, if menopausal status-wise analysis is attempted. Ascertainment of serum lipid/lipoprotein aberrations in breast carcinoma; and substantiation of their behaviour with age and menopause among breast cancer and healthy subjects.
Methods: Laboratory analyses of serum total cholesterol (TC), high density lipoprotein cholesterol (HDL-c), low and very low density lipoproteins (LDL-c, VLDL-c) and triglycerides (TG) were done among breast cancer subjects (n=50) and healthy women (n=50) with respect to their age (3 sub-groups viz. 25-40, 41-55 and 56-75 years) and menopausal status. Grouped numerical data were subjected to intra- and inter-group comparisons using Student’s unpaired-‘t’-test and ANOVA with Post-Hoc comparisons using Tukey-HSD (Honestly-Significant-Difference) Test.
Results: Higher serum LDL-c and TC with lower HDL-c levels were observed among breast carcinoma subjects than healthy women (P=0.004, 0.003, 0.009 respectively). Serum LDL-c elevation in peri- and post-menopausal age (P=0.009), while lowered HDL-c specifically during post-menopausal age (0.004) were significantly evident in breast cancer subjects.
Conclusions: Breast carcinoma has obvious alliance with serum LDL-c, TC and HDL-c aberrations. LDL-c has specific variability during peri-menopausal and post-menopausal ages among breast cancer subjects. HDL-c alteration is mainly concerted for post-menopausal age; while total cholesterol could be a peril throughout. The odds of pooled effect of such aberrations in cancer causation cannot be underrated.
References
Buchwald H. Cholesterol inhibition, cancer and chemotherapy. Lancet. 1992;339:1154-6.
Soma MR, Corsini A, Paoletti A. Cholesterol and mevalonic acid modulation in cell metabolism and multiplication. Toxicol Lett. 1992;64-65:1-15.
Ray G, Hussain SA. Role of lipid, lipoprotein and vitamins in women with breast cancer. Clin Biochem. 2001;34:71-6.
Lane DM, Boatman KK, McCarthy WJ. Serum lipids and lipoproteins in women with breast masses. Breast Cancer Res Treat. 1995;34:161-9.
Hasija K, Bagga HK. Alterations of serum cholesterol and serum lipoprotein in breast cancer of women. Indian J Clin Biochem. 2005;20(1):61-6.
Gillmer MD. Mechanism of action/effects of androgens on lipid metabolism. Int J Fertil. 1992;37(2):83-92.
Lopes D, Sanchez MD, Shea-Eaton W, McLean MP. Estrogen Activates the High-Density Lipoprotein Receptor Gene via Binding to Estrogen Response Elements and Interaction with Sterol Regulatory Element Binding Protein-1A. Endocrinology. 2002;143(6):2155-68.
Owiredu WKBA, Donkor, Addai W, Amidu. Serum lipid profile of breast cancer patients. Pak J Biol Sci. 2009;12(4):332-8.
Lippman ME. Breast Cancer. In: Fauci AS, Braunwald E, Kasper DL, Hauser SL, Longo DL, Jameson JL, editors. Harrison’s Principles of Internal Medicine 16th Ed. New Delhi:Mc-Graw Hill;2005:516-23.
Cholesterol reagent set (Kit insert). Thane (India): Accurex Biomedical Pvt. Ltd; 2009.
HDL-cholesterol reagent set (Kit insert). Thane (India): Accurex Biomedical Pvt. Ltd;2009.
Triglyceride reagent set (Kit insert). Thane (India): Accurex Biomedical Pvt. Ltd; 2009.
Rifai N, Warnick GR. Lipids, lipoproteins, apolipoproteins, and other cardiovascular risk factors. In: Burtis CA, Ashwood ER, Bruns DE, editors. Tietz textbook of clinical chemistry and molecular diagnostics. 4th ed. New Delhi: Saunders Elsevier;2006:948.
De-Waard F, Comelis IP, Aoki K, Yoshida. Breast cancer incidence according to weight and height in two cities of the Netherlands and in Aichi prefecture, Japan. Cancer. 1977;40:1269-75.
Demers LM. The Adrenal Cortex. In: Burtis CA, Ashwood ER, Bruns DE. Tietz textbook of clinical chemistry and molecular diagnostics. 4th ed. New Delhi:Saunders Elsevier;2006:2003-52.
Rifai N, Warnick GR. Lipids Lipoproteins Apolipoproteins and Other Cardiovascular Risk Factors. In: Burtis CA, Ashwood ER, Bruns DE. Tietz textbook of clinical chemistry and molecular diagnostics. 4th ed. New Delhi:Saunders Elsevier;2006:904.
Kumar V, Green S, Stack G, Beny M, Jin JR, Chambon P. Functional domains of the human estrogen receptor. Cell. 1987;51:941-51.
Bernstein L, Ross RK. Endogenous hormones and breast cancer risk. Epidemiol Rev. 1993;15:48-65.
Araki E, Yamaguchi M, Yamamoto H, Inoue G, Tooma H, Ishikawa H et al. Serum lipids in patients with carcinoma and benign diseases of the breast. Jpn J Clin Oncol. 1980;10:211-4.
Lopez-Saez J, Martinez-Rubio JA, Alvarez MM, Carrera CG, Villar MD, Mier AGL, et al. Metabolic profile of breast cancer in a population of women in Southern Spain. Open Clin Cancer J. 2008; 2:1-6.
Furberg AS, Veierod MB, Wilsgaard T, Bernstein L, Thune I. Serum high-density lipoprotein cholesterol, metabolic profile, and breast cancer risk. J Natl Cancer Inst. 2004;96(15):1152-60.
